← All trials
NCT07284134
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2025
- Primary completion
- Oct 13, 2027
- Completion date
- Oct 17, 2028
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 560
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.